

Side Effects Associated with Prostaglandin Analog Ther

Survey of Ophthalmology

53, S93-S105

DOI: [10.1016/j.survophthal.2008.08.004](https://doi.org/10.1016/j.survophthal.2008.08.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences. Survey of Ophthalmology, 2008, 53, S69-S84.	4.0	71
2	Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients. Clinical Ophthalmology, 2009, 3, 493.	1.8	2
3	Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides. Clinical Ophthalmology, 2009, 3, 663.	1.8	12
4	Update and commentary on the pro-drug bimatoprost and a putative "prostamide receptor"™. Expert Review of Ophthalmology, 2009, 4, 477-489.	0.6	11
5	Interaction of Ocular Hypotensive Agents (PGF2± Analogs" Bimatoprost, Latanoprost, and Travoprost) With MDR Efflux Pumps on the Rabbit Cornea. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 487-498.	1.4	29
7	Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety, 2009, 18, i.	1.9	0
8	Pharmacotherapy of intraocular pressure " part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opinion on Pharmacotherapy, 2009, 10, 2859-2870.	1.8	47
9	Latanoprost in pediatric glaucoma" pediatric exposure over a decade. Journal of AAPOS, 2009, 13, 558-562.	0.3	36
10	Extensive facial skin pigmentation after latanoprost treatment. Cutaneous and Ocular Toxicology, 2009, 28, 185-187.	1.3	9
11	Differences Between Applanation Tonometry and Dynamic Contour Tonometry in Prostaglandin Analogue-treated Eyes. Journal of Glaucoma, 2010, 19, 347.	1.6	2
12	Risk factors for subject withdrawals in clinical trials evaluating glaucoma medications. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1007-1012.	1.9	2
13	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clinical Ophthalmology, 2010, 4, 741.	1.8	48
14	Management of hypotrichosis of the eyelashes: Focus on bimatoprost. Clinical, Cosmetic and Investigational Dermatology, 2010, 3, 39.	1.8	22
15	Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects. Clinical Ophthalmology, 2010, 4, 471.	1.8	5
16	Physicians"™ treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma. Current Medical Research and Opinion, 2010, 26, 957-963.	1.9	12
17	Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open"angle glaucoma and ocular hypertension: 24"month results of a randomized, double"masked phase III study. Acta Ophthalmologica, 2010, 88, 12-19.	1.1	100
18	Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth. Dermatologic Surgery, 2010, 36, 1361-1371.	0.8	72
19	Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. , 2010, , CD002898.		33

#	ARTICLE	IF	CITATIONS
20	Hyperemia Reduction After Administration of a Fixed Combination of Bimatoprost and Timolol Maleate to Patients on Prostaglandin or Prostanamide Monotherapy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 611-615.	1.4	9
22	Evaluation of investigator bias in industry-funded clinical trials of latanoprost. <i>Canadian Journal of Ophthalmology</i> , 2011, 46, 531-536.	0.7	4
25	Enhanced Eyelashes: Prescription and Over-the-Counter Options. <i>Aesthetic Plastic Surgery</i> , 2011, 35, 116-121.	0.9	37
26	Central Serous Chorioretinopathy Associated with Topical Latanoprost Therapy. <i>Ocular Immunology and Inflammation</i> , 2011, 19, 453-455.	1.8	15
27	Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature. <i>British Journal of Ophthalmology</i> , 2011, 95, 1490-1495.	3.9	12
28	Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 463-471.	1.8	11
29	Intracellular Signaling in Human Iridial Fibroblasts and Iridial Melanocytes in Response to Prostaglandins, Endothelin, Isoproterenol, and Other Pharmacological Agents. <i>Current Eye Research</i> , 2011, 36, 310-320.	1.5	5
30	Primer AÃÃk AÃÃlÃk Glokom ve PsÃdoeksfoliatif Glokomda, Mitomisin CÃmlÃ TrabekÃlektominin MakÃlÃ KalÃnlÃk AÃzerine Olan Etkisinin KÃyaslanmasÃ. TÃrk Oftalmoloji Dergisi, 2012, 42, 1-4.	0.9	1
31	Retinal Complications after Damaging the Vitreolenticular Barrier. <i>Ophthalmologica</i> , 2012, 227, 20-33.	1.9	16
32	Spanish multicenter tafluprost tolerability study. <i>British Journal of Ophthalmology</i> , 2012, 96, 826-831.	3.9	15
33	Comparison of a Travoprost BAK-Free Formulation Preserved with Polyquaternium-1 with BAK-Preserved Travoprost in Ocular Hypertension or Open-Angle Glaucoma. <i>European Journal of Ophthalmology</i> , 2012, 22, 34-44.	1.3	44
34	Periocular Changes Following Long-Term Administration of Latanoprost 0.005%. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2012, 28, e42-e43.	0.8	28
37	Eyelash alopecia areata: case series and literature review. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, 333-338.	0.7	11
38	A review of the use of latanoprost for glaucoma since its launch. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 723-745.	1.8	67
39	Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2012, 153, 1187-1196.	3.3	40
40	A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 794-800.	1.2	104
41	A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125Ãg/mL to latanoprost 50Ãg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension. <i>BMC Ophthalmology</i> , 2012, 12, 9.	1.1	17
42	Integumentary System. , 2012, , 11-68.		3

#	ARTICLE	IF	CITATIONS
43	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2012, 34, 761-768.	0.6	0
44	Lower eyelid melanoma during bimatoprost (Lumigan) therapy. Clinical and Experimental Ophthalmology, 2012, 40, 213-214.	2.6	5
45	Short- and long-term corneal vascular effects of tafluprost eye drops. Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251, 1919-1927.	1.9	4
46	Cytomegalovirus anterior uveitis in immunocompetent individuals following topical prostaglandin analogues. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 55.	2.2	12
47	Conjunctival changes and inflammatory aspects in rabbits' conjunctivas induced by fixed combinations of prostaglandin analogues and timolol maleate. Journal of Ophthalmic Inflammation and Infection, 2013, 3, 22.	2.2	10
48	Latanoprost/timolol fixed combination for the treatment of glaucoma. Expert Opinion on Pharmacotherapy, 2013, 14, 1815-1827.	1.8	11
49	Tubulointerstitial Nephritis and Uveitis Syndrome in Children: A Prospective Multicenter Study. Ophthalmology, 2013, 120, 1476-1481.	5.2	50
50	Drug-Induced Macular Edema. Drugs, 2013, 73, 789-802.	10.9	37
51	Conjunctival modifications induced by medical and surgical therapies in patients with glaucoma. Current Opinion in Pharmacology, 2013, 13, 56-64.	3.5	56
52	Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Japanese Journal of Ophthalmology, 2013, 57, 179-184.	1.9	40
53	Acute Effects of Glaucoma Medications and Benzalkonium Chloride on Pre-adipocyte Proliferation and Adipocyte Cytotoxicity In Vitro. Current Eye Research, 2013, 38, 70-74.	1.5	14
55	In vivo confocal microscopy of meibomian glands in glaucoma. British Journal of Ophthalmology, 2013, 97, 343-349.	3.9	62
56	A Review of the Medical Treatment of Pediatric Glaucomas at Moorfields Eye Hospital. Journal of Glaucoma, 2013, 22, 601-607.	1.6	29
57	Safety Assessment of Subconjunctivally Implanted Devices Containing Latanoprost in Dutch-Belted Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 574-585.	1.4	12
58	Ocular Toxicity Assessment From Systemically Administered Xenobiotics. International Journal of Toxicology, 2013, 32, 171-188.	1.2	14
59	ATP-Sensitive Potassium (KATP) Channel Openers Diazoxide and Nicorandil Lower Intraocular Pressure In Vivo. , 2013, 54, 4892.		20
60	A Cross-Sectional Survey of the Association between Bilateral Topical Prostaglandin Analogue Use and Ocular Adnexal Features. PLoS ONE, 2013, 8, e61638.	2.5	73
61	Glaucoma associated with the management of rhegmatogenous retinal detachment. Clinical Ophthalmology, 2013, 7, 727.	1.8	29

#	ARTICLE	IF	CITATIONS
62	Latanoprost in the treatment of glaucoma. <i>Clinical Ophthalmology</i> , 2014, 8, 1967.	1.8	70
63	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy. <i>Clinical Ophthalmology</i> , 2014, 8, 543.	1.8	10
64	Glaucoma management: relative value and place in therapy of available drug treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 30-43.	2.5	62
65	Late-day intraocular pressure—lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. <i>BMC Ophthalmology</i> , 2014, 14, 151.	1.4	8
66	Long-term efficacy of latanoprost in primary congenital glaucoma. <i>Eye</i> , 2014, 28, 53-57.	2.1	16
67	Effectiveness of the ICare rebound tonometer in patients with overestimated intraocular pressure due to tight orbit syndrome. <i>Japanese Journal of Ophthalmology</i> , 2014, 58, 496-502.	1.9	12
68	Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. <i>Japanese Journal of Ophthalmology</i> , 2014, 58, 212-217.	1.9	38
69	Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. <i>Eye</i> , 2014, 28, 1446-1451.	2.1	29
70	Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles. , 2014, 55, 7387.		64
71	A general analytical platform and strategy in search for illegal drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 215-229.	2.8	42
72	Determination of prostaglandin analogs in cosmetic products by high performance liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1359, 140-146.	3.7	12
73	Management of Hypotrichosis of the Eyelashes. <i>Plastic Surgical Nursing</i> , 2015, 35, 82-91.	0.3	5
74	Prenatal exposure to common environmental factors affects brain lipids and increases risk of developing autism spectrum disorders. <i>European Journal of Neuroscience</i> , 2015, 42, 2742-2760.	2.6	63
75	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. <i>Clinical Ophthalmology</i> , 2015, 9, 633.	1.8	17
77	Pharmacology of topical prostaglandin F ₂ analogs and their place in the treatment of glaucoma in small animals. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2015, 38, 105-112.	1.3	5
78	Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 74-75.	0.4	1
79	Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. <i>The Cochrane Library</i> , 2015, 2015, CD002898.	2.8	84
80	The effect of latanoprost on vitiligo: a preliminary comparative study. <i>International Journal of Dermatology</i> , 2015, 54, 587-593.	1.0	44

#	ARTICLE	IF	CITATIONS
81	Periocular skin hyperpigmentation in children treated with prostaglandin analogues. <i>Journal of AAPOS</i> , 2015, 19, 49-53.	0.3	5
82	Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 609-617.	2.4	18
83	Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 74-75.	0.4	5
84	Evaluation of Physical Properties of Generic and Branded Travoprost Formulations. <i>Journal of Current Glaucoma Practice</i> , 2016, 10, 49-55.	0.5	6
85	Selective laser trabeculoplasty as an initial treatment option for open-angle glaucoma. <i>Arquivos Brasileiros De Oftalmologia</i> , 2016, 79, 417-421.	0.5	7
86	Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-22.	1.3	70
87	Bimatoprost Induced Serous Macular Detachment after Cataract Surgery. <i>Case Reports in Ophthalmological Medicine</i> , 2016, 2016, 1-3.	0.5	1
88	Inter-Rater Agreement in the Assessment of Video Recordings of Eye Drop Instillation by Glaucoma Patients. <i>PLoS ONE</i> , 2016, 11, e0145764.	2.5	2
89	Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. <i>International Journal of Clinical Practice</i> , 2016, 70, 577-586.	1.7	6
90	Prostaglandin Eyedrops Are Associated With Decreased Thicknesses of Eyelid Dermis and Orbicularis Oculi Muscle: Ultrasonographic Findings. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2016, 32, 337-341.	0.8	7
91	The Impact of Glaucoma Medications on Corneal Wound Healing. <i>Journal of Glaucoma</i> , 2016, 25, 122-127.	1.6	23
92	The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction. <i>Journal of Glaucoma</i> , 2016, 25, 770-774.	1.6	50
93	A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabectedin in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 555-562.	1.4	49
94	Pediatric Glaucoma: Pharmacotherapeutic Options. <i>Paediatric Drugs</i> , 2016, 18, 209-219.	3.1	13
95	Effect of Travoprost and Nonsteroidal Anti-Inflammatory Drug on Diurnal Intraocular Pressure in Normal Subjects with Low-Ten Baseline Intraocular Pressure. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 365-370.	1.4	3
96	Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1201-1208.	4.1	10
97	Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 117-128.	2.4	7
98	Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs. <i>Cutaneous and Ocular Toxicology</i> , 2017, 36, 9-11.	1.3	0

#	ARTICLE	IF	CITATIONS
99	Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017, 33, 170-175.	1.4	14
100	Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. <i>American Journal of Ophthalmology</i> , 2017, 175, 137-147.	3.3	98
101	Structural and Histologic Eyelid Changes Associated with 6 Months of Topical Bimatoprost in the Rabbit. <i>Journal of Glaucoma</i> , 2017, 26, 253-257.	1.6	4
102	Latanoprost-induced Skin Depigmentation. <i>Journal of Glaucoma</i> , 2017, 26, e246-e248.	1.6	10
103	Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification. <i>International Ophthalmology</i> , 2017, 37, 1147-1153.	1.4	1
104	Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy. <i>Journal of Cosmetic Dermatology</i> , 2017, 16, 18-20.	1.6	9
105	Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations. <i>International Ophthalmology</i> , 2017, 37, 423-428.	1.4	12
106	Factors Related to Prostaglandin-Associated Periorbitopathy in Glaucoma Patients. <i>Asia-Pacific Journal of Ophthalmology</i> , 2017, 6, 238-242.	2.5	11
107	Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy. <i>PLoS ONE</i> , 2017, 12, e0181550.	2.5	28
108	Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents. , 2017, 58, 5731.		24
109	Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. <i>Journal of Glaucoma</i> , 2018, 27, 7-15.	1.6	59
110	Reversal of retinal pigment epithelial detachment after cessation of topical travoprost therapy. <i>International Ophthalmology</i> , 2018, 38, 2227-2231.	1.4	3
111	Topical prostaglandin analogues and development of epiretinal membrane. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2018, 93, 169-173.	0.2	0
112	Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. <i>Acta Ophthalmologica</i> , 2018, 96, e577-e581.	1.1	22
113	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. <i>Drugs</i> , 2018, 78, 39-64.	10.9	43
114	RESOLUTION OF A MACULAR HOLE COMPLICATING A PSEUDOPHAKIC MACULAR EDEMA WITH NONSURGICAL TREATMENT. <i>Retinal Cases and Brief Reports</i> , 2018, 12, 131-135.	0.6	11
115	Análogos de prostaglandinas y desarrollo de membrana epirretinal. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2018, 93, 169-173.	0.2	1
116	Trends in the characteristics of vitrectomy in Eastern China. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1993-2000.	1.8	2

#	ARTICLE	IF	CITATIONS
117	Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice. <i>Scientific Reports</i> , 2018, 8, 13088.	3.3	0
118	A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. <i>American Journal of Ophthalmology</i> , 2018, 196, 101-111.	3.3	10
119	Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2018, 34, 531-537.	1.4	72
121	Corneal Edema and Opacification Preferred Practice Pattern®. <i>Ophthalmology</i> , 2019, 126, P216-P285.	5.2	20
122	Dry Eye Symptoms and Ocular Pain in Veterans with Glaucoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1076.	2.4	17
123	Efficacy And Safety Of Travoprost Versus Timolol To Treat Early-Onset Ocular Hypertension Secondary To Vitrectomy: A Randomized Trial. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3453-3463.	4.3	2
124	Once Daily Pregabalin Eye Drops for Management of Glaucoma. <i>ACS Nano</i> , 2019, 13, 13728-13744.	14.6	27
125	Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 793-803.	5.0	25
126	Does using topical latanoprost affect subfoveal choroidal thickness?. <i>Cutaneous and Ocular Toxicology</i> , 2019, 38, 370-374.	1.3	3
127	Medical Therapy for Glaucoma-IOP Lowering Agents. , 2019, , 115-135.		1
128	Marine-Steroid Derivative 5 α -Androst-3 β , 5 α , 6 β -triol Protects Retinal Ganglion Cells from Ischemia-Reperfusion Injury by Activating Nrf2 Pathway. <i>Marine Drugs</i> , 2019, 17, 267.	4.6	12
129	Primary angle-closure glaucoma with goniodysgenesis in a Beagle dog. <i>BMC Veterinary Research</i> , 2019, 15, 75.	1.9	6
131	Current management of glaucoma. <i>Medical Journal of Australia</i> , 2019, 210, 180-187.	1.7	206
132	Analysis of Bimatoprost-Induced changes on Rabbits eyelash Follicle: Clinical and Electron microscopic study. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 2421-2426.	1.8	1
133	Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. <i>Journal of Glaucoma</i> , 2019, 28, 375-385.	1.6	43
134	The protective effect of 3% diquafosol on meibomian gland morphology in glaucoma patients treated with prostaglandin analogs: a 12-month follow-up study. <i>BMC Ophthalmology</i> , 2020, 20, 277.	1.4	5
135	The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 529-533.	1.4	17
136	The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 539-548.	3.2	22

#	ARTICLE	IF	CITATIONS
137	Distribution of 14C-Latanoprost Following a Single Intracameral Administration Versus Repeated Topical Administration. <i>Ophthalmology and Therapy</i> , 2020, 9, 929-940.	2.3	3
138	Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma. <i>Ophthalmology and Therapy</i> , 2020, 9, 1041-1053.	2.3	10
139	Effectiveness of Blepharoptosis Surgery in Patients With Deepening of the Upper Eyelid Sulcus. <i>Journal of Craniofacial Surgery</i> , 2020, 31, 1284-1286.	0.7	1
140	Prostaglandin-Associated Periorbitopathy in Children and Young Adults with Glaucoma. <i>Ophthalmology Glaucoma</i> , 2020, 3, 288-294.	1.9	3
141	Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2020, 220, 53-63.	3.3	67
142	VIP Induces Changes in the F-/G-Actin Ratio of Schlemm's Canal Endothelium via LRRK2 Transcriptional Regulation. , 2020, 61, 45.		8
143	Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1). <i>Ophthalmology</i> , 2020, 127, 1627-1641.	5.2	62
144	Prostaglandin F ₂ ± Agonists Negatively Modulate the Size of 3D Organoids from Primary Human Orbital Fibroblasts. , 2020, 61, 13.		46
145	In vivo confocal microscopy: qualitative investigation of the conjunctival and corneal surface in open angle glaucomatous patients undergoing the XEN-Gel implant, trabeculectomy or medical therapy. <i>Eye and Vision (London, England)</i> , 2020, 7, 15.	3.0	20
146	Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 162-169.	1.4	27
147	Matrix Metalloproteinases and Glaucoma Treatment. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 208-228.	1.4	70
148	Drugs Used in Ophthalmology. , 2021, , 413-499.		0
149	Examination of retinal vascular density changes via optical coherence tomography angiography in patients with glaucoma. <i>International Ophthalmology</i> , 2021, 41, 687-698.	1.4	3
150	The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 453-466.	2.4	16
151	Corneal topographic changes after blepharoptosis surgery in patients with deepening of the upper eyelid sulcus. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 282-287.	1.9	3
152	Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products. <i>Dermatologic Surgery</i> , 2021, 47, 658-665.	0.8	7
153	Complications and adverse effects of periocular aesthetic treatments. <i>Survey of Ophthalmology</i> , 2022, 67, 741-757.	4.0	12
154	Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts. <i>Translational Vision Science and Technology</i> , 2021, 10, 6.	2.2	8

#	ARTICLE	IF	CITATIONS
155	Simultaneous Use of ROCK Inhibitors and EP2 Agonists Induces Unexpected Effects on Adipogenesis and the Physical Properties of 3T3-L1 Preadipocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4648.	4.1	8
156	Prostaglandin F2 \pm and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave's orbitopathy related human orbital fibroblasts. <i>Experimental Eye Research</i> , 2021, 205, 108489.	2.6	13
157	Prostaglandin F2 \pm agonists induced enhancement in collagen1 expression is involved in the pathogenesis of the deepening of upper eyelid sulcus. <i>Scientific Reports</i> , 2021, 11, 9002.	3.3	14
158	Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2021, 37, 223-229.	1.4	14
159	Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. <i>Pharmaceuticals</i> , 2021, 14, 501.	3.8	6
160	In vivo drug delivery via contact lenses: The current state of the field from origins to present. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102413.	3.0	8
161	Adverse effects of prostaglandin analogues used in ophthalmological practice. <i>Rossiiskii Oftal'mologicheskii Zhurnal</i> , 2021, 14, 85-89.	0.4	3
162	Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 591-597.	1.9	10
163	Screening of the Drug-Induced Effects of Prostaglandin EP2 and FP Agonists on 3D Cultures of Dexamethasone-Treated Human Trabecular Meshwork Cells. <i>Biomedicines</i> , 2021, 9, 930.	3.2	12
164	In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy. <i>Pharmaceuticals</i> , 2021, 14, 887.	3.8	6
165	Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy. <i>Medicine (United States)</i> , 2021, 100, e26874.	1.0	7
166	Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 810-819.	1.9	24
167	Long-acting drug delivery systems for ocular therapies. , 2022, , 61-81.		1
168	Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. <i>PLoS ONE</i> , 2018, 13, e0191398.	2.5	16
170	Prostaglandin analogues: past, present, and future. <i>Ophthalmology Journal</i> , 2017, 10, 40-52.	0.2	13
171	Topical Prostaglandin Analogues and Conjunctival Inflammation in Uveitic Glaucoma. <i>Open Ophthalmology Journal</i> , 2012, 6, 75-78.	0.2	8
172	Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension. <i>Open Ophthalmology Journal</i> , 2018, 12, 110-120.	0.2	2
173	The Diagnosis and Treatment of Glaucoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 225-234.	0.9	106

#	ARTICLE	IF	CITATIONS
174	Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. Health Technology Assessment, 2019, 23, 1-102.	2.8	42
175	Intraocular pressure changes during and after silicone oil endotamponade (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1.	1.8	15
176	Repigmentation of hypopigmented scars using combination of fractionated carbon dioxide laser with topical latanoprost vs. fractionated carbon dioxide laser alone. Indian Journal of Dermatology, 2015, 60, 364.	0.3	14
177	Medical management of glaucoma: Principles and practice. Indian Journal of Ophthalmology, 2011, 59, 88.	1.1	30
178	Severe cutaneous reaction to latanoprost eye drops. Journal of Ophthalmic and Vision Research, 2018, 13, 348.	1.0	2
179	Reversible Corneal Decompensation Caused by a Topical Dorzolamide/Timolol Fixed Combination After Descemet Stripping Automated Endothelial Keratoplasty. Cornea, 2021, Publish Ahead of Print, .	1.7	2
180	Segmentites antérieures à virus de la famille Herpes. , 2010, , 245-271.		0
181	Uvérites médicamenteuses. , 2010, , 535-545.		0
182	Drugs used in ocular treatment. Side Effects of Drugs Annual, 2011, , 977-988.	0.6	0
183	Contact Dermatitis and Drug Eruptions. , 2011, , 88-137.		1
184	Pressure Lowering Medications. , 0, , .		0
186	Preserved to preservative free prostaglandin analogues in primary open angle glaucoma. International Journal of Basic and Clinical Pharmacology, 2013, 2, 696.	0.1	0
187	Drug-induced ocular side effects. , 2015, , 47-343.		0
188	What's New in Medical Management of Glaucoma. Current Practices in Ophthalmology, 2019, , 47-64.	0.1	0
189	Impact of tafluprost and tafluprost/timolol on the thickness of the retina in the macular area. Rossiiskii Oftalmologicheskii Zhurnal, 2019, 12, 18-24.	0.4	1
190	Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2). Drugs, 2021, 81, 2017-2033.	10.9	25
191	Medical Therapy in Angle Closure Glaucoma. , 2021, , 31-44.		0
192	Topical latanoprost solution in combination with microneedling in treatment of segmental vitiligo. Al-Azhar Assiut Medical Journal, 2020, 18, 486.	0.0	0

#	ARTICLE	IF	CITATIONS
193	Conjunctival Implantation Cyst in the Orbicularis Oculi Muscle: Review of a Possible Origin From Displaced Stem Cells With a Differential Diagnosis. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, 1-11.	0.8	1
194	Immunologic corneal graft rejection after administration of topical latanoprost: a report of two patients. <i>Journal of Ophthalmic and Vision Research</i> , 2011, 6, 127-30.	1.0	2
195	Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 17-29.	0.1	0
196	An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 61-66.	0.1	0
197	Herbal medicine for ocular diseases: An age old therapy and its future perspective. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 68, 102979.	3.0	4
198	Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Graves's™ Orbitopathy. <i>Cells</i> , 2021, 10, 3196.	4.1	2
200	Glaucoma: A review for the family physician. <i>Osteopathic Family Physician</i> , 2022, , 35-41.	0.1	0
201	Dermatological adverse effects of anti-glaucoma eye drops: a review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 661-670.	2.4	5
202	Hypertrichosis and topical corticosteroid use. <i>Cleveland Clinic Journal of Medicine</i> , 2022, 89, 71-72.	1.3	0
204	Vitreectomy in Diabetic Retinopathy. , 0, , .		0
206	The risk of uveitis due to prostaglandin analogs in pediatric glaucoma. <i>Journal of AAPOS</i> , 2022, , .	0.3	3
207	Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation. <i>Current Research in Neurobiology</i> , 2022, 3, 100037.	2.3	5
208	Childhood Glaucoma and Medical Treatment: An Up to Date. , 0, , .		0
209	Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. <i>Sexual Medicine Reviews</i> , 2022, 10, 764-781.	2.9	3
210	Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	10
211	Surgical Results of Trabeculectomy among Groups Stratified by Prostaglandin-Associated Periorbitopathy Severity. <i>Ophthalmology</i> , 2023, 130, 297-303.	5.2	3
212	Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2023, 39, 63-69.	1.4	1
213	Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats. <i>Communications Biology</i> , 2022, 5, .	4.4	5

#	ARTICLE	IF	CITATIONS
214	Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells. PLoS ONE, 2023, 18, e0280331.	2.5	3
215	Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant. , 2023, 64, 15.		5
216	Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment. Trk Oftalmoloji Dergisi, 2023, 53, 8-12.	0.9	0
217	Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness. Experimental Eye Research, 2023, 232, 109444.	2.6	3
218	Screening, characterization, and determination of suspected additives bimatoprost and latanoprost in cosmetics using NMR and LC-MS methods. Analytical and Bioanalytical Chemistry, 2023, 415, 3549-3558.	3.7	2
219	Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients. Pharmaceuticals, 2023, 16, 791.	3.8	2
220	Selective laser trabeculoplasty: physiology and effects of SLT. , 2023, , 209-216.		0
221	Case Report: Scleral hyperpigmentation associated with oral hydroxychloroquine use. Frontiers in Ophthalmology, 0, 3, .	0.5	0
222	Impact and Management of Loss of Eyebrows and Eyelashes. Dermatology and Therapy, 2023, 13, 1243-1253.	3.0	0
223	Qualitative Development of the Allergan Satisfaction with Treatment Experience Questionnaire (ASTEQ) Instrument, a Patient-Reported Outcome Measure in Glaucoma and Ocular Hypertension. Ophthalmology and Therapy, 0, , .	2.3	0
224	Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension. Journal of Korean Ophthalmological Society, 2023, 64, 819-824.	0.2	0
225	Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 µg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension. Clinical Ophthalmology, 0, Volume 17, 3023-3036.	1.8	0
226	Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery. Journal Francais D'Ophthalmologie, 2024, 47, 103996.	0.4	0
227	Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug. Current Opinion in Pharmacology, 2024, 74, 102426.	3.5	0
228	Atopic Disease as a Risk Factor for Recurrent Herpetic Keratitis. Microorganisms, 2024, 12, 220.	3.6	0
229	Preparation and characterization of vinyl silica-supported surface molecularly imprinted polymers coupled with liquid chromatography-mass spectrometry for extraction of prostaglandin analogs from cosmetic products. Separation Science Plus, 0, , .	0.6	0